Quarterly ResultMay 13, 2026, 04:12 PM
Dermata Therapeutics to Launch Tome Skincare Brand, Reports Q1 2026 Results
AI Summary
Dermata Therapeutics announced its new direct-to-consumer (DTC) skincare brand, Tome, and plans to launch its first product, the Tome Foundational Treatment, a once-weekly mask, in mid-2026. The company also reported a net loss of $1.8 million for Q1 2026, an improvement from $2.3 million in Q1 2025. Dermata raised $2.0 million in net proceeds from its at-the-market (ATM) financing facility, which is expected to fund operations into Q1 2027.
Key Highlights
- Plans to launch its first DTC product, Tome Foundational Treatment, in mid-2026.
- Raised $2.0 million in net proceeds from ATM financing in Q1 2026.
- Cash and cash equivalents were $6.9 million as of March 31, 2026, down from $7.5 million.
- Reported a net loss of $1.8 million for Q1 2026, compared to $2.3 million in Q1 2025.
- Research and development expenses decreased to $0.4 million in Q1 2026 from $1.3 million in Q1 2025.
- Selling, general and administrative expenses increased to $1.5 million in Q1 2026 from $1.1 million in Q1 2025.
- Current cash resources are expected to fund operations into the first quarter of 2027.
- Hired Kyra Peckaitis as Vice President of Marketing for the new Tome skincare brand.